InvestorsHub Logo
Followers 17
Posts 5459
Boards Moderated 1
Alias Born 05/10/2019

Re: None

Saturday, 11/23/2019 10:56:00 AM

Saturday, November 23, 2019 10:56:00 AM

Post# of 38
Kazia Therapeutics- $KZIA - Data presented this weekend -2019 SNO Conference . Halt lifted Monday morning. Expecting a $KRTX like move. CEO link on recent webcast suggest successful data here and co should be valued between 200-$500 million at this point of data is positive
Conservatively this is $45-$60 company given its potential and how easy and quick this will be FDA approved. They’re funded and they expect a “LARGER PHARMA” to bring GDC-0084 to fruition.


For GDC 0084 to work this well as a monotherapy it will CERTAINLY raise eyebrows of the worlds best experts over the weekend. Look who is presenting the data non other than Prof Wen!!!!




Dana Farber - Harvard Medical - MD Anderson - UCLA - Stephenson Cancer - John Theurer - Genetech

Poster Presenting Author(s)

Patrick Wen
Director, Center For Neuro-Oncology

ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KZIA News